```html

Zollinger‑Ellison Syndrome (Gastrinoma) – A Comprehensive Medical Guide

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder characterized by one or more gastrin‑producing tumors (gastrinomas) that arise most often in the pancreas or duodenum. These tumors secrete excessive amounts of the hormone gastrin, leading to hyperacidity in the stomach. The resulting acid overload damages the lining of the stomach and small intestine, causing severe peptic ulcers and a range of gastrointestinal (GI) symptoms.

• Incidence: Approximately 0.5–2 cases per million people per year.
• Prevalence: About 1 in 100,000 people worldwide are estimated to have ZES.
• Age & gender: Most patients are diagnosed between 30–60 years of age; slight male predominance (≈55%).
• Associated conditions: 20–30 % of cases occur as part of the inherited multiple endocrine neoplasia type 1 (MEN‑1) syndrome.

Symptoms

Because gastrin excess leads to continuous stomach acid secretion, ZES presents with a spectrum of GI and systemic symptoms. Not every patient experiences all of these, and the severity can vary widely.

Gastrointestinal Symptoms

• Recurrent peptic ulcers: Ulcers may appear in atypical locations (duodenum, jejunum, jejunal loops) and tend to recur despite standard therapy.
• Severe abdominal pain: Cramping or burning pain that worsens after meals.
• Diarrhea: Occurs in 30–50 % of patients; can be watery, fatty (steatorrhea) or both due to acid inactivation of pancreatic enzymes.
• Heartburn & gastro‑esophageal reflux disease (GERD): Persistent burning sensation behind the breastbone.
• Nausea & vomiting: May be triggered by acid‑induced irritation.
• Gastrointestinal bleeding: Ulcer erosion can lead to melena or hematemesis.

Systemic Symptoms

• Weight loss: Result of malabsorption and chronic diarrhea.
• Fatigue & weakness: Secondary to anemia or nutrient deficiencies.
• Osteoporosis: Chronic acid can impair calcium absorption.
• Skin changes: Rare, but some patients develop hyperpigmentation.

Causes and Risk Factors

Zollinger‑Ellison syndrome is caused by gastrin‑secreting neuroendocrine tumors. The exact trigger for sporadic (non‑inherited) gastrinomas is unknown, but several factors increase risk.

Primary Causes

• Gastrinomas: Usually located in the duodenum (≈60 %) or pancreas (≈30 %); the remainder are found in lymph nodes or rare ectopic sites.
• Multiple endocrine neoplasia type 1 (MEN‑1): An autosomal‑dominant hereditary syndrome caused by mutations in the MEN1 tumor suppressor gene.

Risk Factors

• Family history of MEN‑1 or known MEN1 gene mutation.
• Previous history of pancreatic neuroendocrine tumors.
• Age 30–60 years (peak incidence).
• Radiation exposure to the abdomen (very limited evidence, but some case reports suggest a possible link).

Diagnosis

Diagnosing ZES requires a combination of biochemical testing, imaging, and endoscopic evaluation. Early recognition is crucial because ulcers tend to be refractory to standard treatment.

Biochemical Tests

• Fasting serum gastrin level: Values > 1000 pg/mL (normal < 100 pg/mL) are highly suggestive, especially when gastric pH < 2.
• Secretin stimulation test: In ZES, gastrin paradoxically rises > 120 pg/mL after IV secretin (normal response is a decrease).
• Gastric pH measurement: Persistent acidity (pH < 2) supports the diagnosis.

Imaging Studies

• Somatostatin receptor scintigraphy (Octreoscan) or Ga‑68 DOTATATE PET/CT: Highly sensitive for locating gastrinomas.
• CT or MRI of the abdomen: Identifies tumor size, location, and potential metastases.
• EUS (Endoscopic Ultrasound): Useful for detecting small duodenal lesions (< 1 cm).

Endoscopic Evaluation

• Upper endoscopy (EGD): Visualizes ulcers, assesses for bleeding, and may obtain biopsies to rule out malignancy.

Diagnostic Criteria (simplified)

1. Fasting gastrin > 1000 pg/mL + gastric pH < 2, or
2. Fasting gastrin > 150 pg/mL with a positive secretin test, and
3. Imaging that localizes a gastrin‑secreting tumor.

Treatment Options

Treatment aims to control acid hypersecretion, eradicate or control the tumor, and manage symptoms.

Acid‑Suppressive Medications

• Proton pump inhibitors (PPIs): Omeprazole, esomeprazole, or pantoprazole are first‑line; high‑dose regimens (e.g., omeprazole 60 mg daily) are often required.
• H2‑receptor antagonists: Cimetidine or ranitidine can be adjuncts but are less effective than PPIs.

Tumor‑Directed Therapies

• Surgical resection: Curative for localized gastrinomas; laparoscopic or open approaches depending on size.
• Enucleation: For small (< 2 cm) well‑defined tumors without invasion.
• Somatostatin analogs (e.g., octreotide, lanreotide): Control hormone secretion and may shrink tumors; especially useful in metastatic disease.
• Targeted systemic therapy: Everolimus or sunitinib for advanced pancreatic neuroendocrine tumors.
• Peptide receptor radionuclide therapy (PRRT): ^177Lu‑DOTATATE for somatostatin‑receptor‑positive metastases.
• Chemotherapy: Reserved for aggressive, poorly differentiated tumors.

Liver‑Directed Treatments (for metastases)

• Radiofrequency ablation, hepatic artery embolization, or liver transplantation in select cases.

Lifestyle & Supportive Measures

• Small, frequent meals to minimize acid spikes.
• Avoidance of alcohol, caffeine, and NSAIDs, which aggravate ulcer disease.
• Calcium and vitamin D supplementation (to protect bone health).
• Regular monitoring of serum gastrin, gastric pH, and imaging every 6–12 months.

Living with Zollinger‑Ellison Syndrome (Gastrinoma)

Long‑term management requires a partnership between the patient, gastroenterologist, endocrine surgeon, and, when needed, an oncologist.

Daily Management Tips

• Medication adherence: Take PPIs exactly as prescribed; never skip doses.
• Medication timing: PPIs are most effective when taken 30 minutes before a meal.
• Monitor symptoms: Keep a daily diary of pain, stool frequency, and any bleeding.
• Nutrition: Focus on a balanced diet rich in protein, whole grains, and non‑acidic fruits/vegetables. Consider a low‑fat diet if malabsorption is present.
• Bone health: Get a DEXA scan every 1–2 years; supplement calcium (1,200 mg/day) and vitamin D (800–1,000 IU/day) as advised.
• Vaccinations: If you receive immunosuppressive therapy (e.g., everolimus), stay up to date on flu, pneumococcal, and COVID‑19 vaccines.
• Psychosocial support: Join patient support groups (e.g., North American Neuroendocrine Tumor Society) to share experiences.

Follow‑Up Schedule (typical)

1. Every 3 months: symptom review, serum gastrin, and liver panel.
2. Every 6–12 months: imaging (CT/MRI or Ga‑68 DOTATATE PET) to detect recurrence.
3. Annually: DEXA scan and assessment of nutritional status.

Prevention

Because most gastrinomas are sporadic, primary prevention is limited. However, certain steps can lower overall risk or aid early detection:

• Genetic counseling: Individuals with a family history of MEN‑1 should undergo testing for MEN1 mutations.
• Avoid chronic high‑dose proton pump inhibitor misuse: While PPIs treat ZES, unnecessary long‑term use without medical supervision can mask early symptoms of gastrinoma.
• Healthy lifestyle: Maintaining a healthy weight and limiting alcohol reduces the likelihood of other GI diseases that could complicate diagnosis.

Complications

If left untreated or inadequately controlled, ZES can lead to serious health problems.

• Perforated ulcer: A hole in the stomach or duodenal wall causing acute abdominal pain and peritonitis.
• Gastrointestinal bleeding: May require endoscopic hemostasis, transfusion, or surgery.
• Malabsorption & nutritional deficiencies: Chronic diarrhea can cause loss of fat‑soluble vitamins (A, D, E, K) and electrolytes.
• Metastatic disease: Approximately 25–35 % of gastrinomas are malignant at diagnosis; common sites include liver and lymph nodes.
• Recurrent ulcer disease: Increases risk of stricture formation and gastric outlet obstruction.
• Bone demineralization: Chronic acid reduces calcium absorption, raising osteoporosis risk.
• Reduced quality of life: Persistent pain, frequent hospital visits, and anxiety about cancer progression.

When to Seek Emergency Care

References

• Mayo Clinic. “Zollinger‑Ellison syndrome.” mayoclinic.org. Accessed May 2026.
• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Zollinger‑Ellison Syndrome.” niddk.nih.gov. Accessed May 2026.
• Cleveland Clinic. “Gastrinoma (Zollinger‑Ellison Syndrome).” clevelandclinic.org. Accessed May 2026.
• World Health Organization. “Neuroendocrine Tumors.” WHO Classification of Tumours, 5th Edition. 2022.
• W. A. Norton, et al. “Management of Gastrinomas and Zollinger‑Ellison Syndrome.” The Journal of Gastroenterology, 2021; 56(4): 321‑334.
• American College of Gastroenterology. “Guideline: Diagnosis and Management of Peptic Ulcer Disease.” 2023.

```